Show simple item record

dc.contributor.advisorO'Reilly, Jamesen
dc.contributor.authorRoss, Laura*
dc.date.accessioned2010-03-19T12:25:13Z
dc.date.available2010-03-19T12:25:13Z
dc.date.issued2009
dc.identifier.urihttp://hdl.handle.net/10034/94567
dc.description.abstractBee products such as honey and propolis have been used medicinally for centuries. More recent research has seen specific types of honey such as manuka honey used in wound healing and propolis as a constituent of mouthwashes and throat lozenges. The present study determined the antioxidant and antimicrobial activities of a number of widely available bee products in the UK. The disc diffusion method was utilised to assess the antibacterial activity of the bee products using a range of bacteria known to cause infection in humans. The ferric- reducing antioxidant power (FRAP) assay was utilised to assess the antioxidant activity of the bee products. The results demonstrated that bee products had antibacterial and antioxidant capacity but with considerable variation. The most potent effect was observed using manuka 30+ against S.epidermidis (33mm mean zone of inhibition when applied undiluted compared to 11mm when using standard honey). Other bee products were of much less potency including propolis which demonstrated no significant antimicrobial activity. However, the antioxidant capacity of propolis tablets was 95 µmol/l per 1mg/ml (95,000 µmol/l per 1 gram tablet). The most potent honey tested was manuka 30+ which was 9.0 µmol/l per 1mg/ml (4500µmol/l for a 5g portion) compared with standard honey 5.0 µmol/l per 1mg/ml (2500 µmol/l for a 5g portion).The antioxidant activity of propolis was also demonstrated in human saliva. The FRAP value of the saliva from a single human subject was evaluated following the intake of propolis containing lozenges compared with a control (boiled sweet). These biological effects may be significant in vivo and have particular relevant in the prevention in disease in humans. However, further work is needed in the form of randomised controlled trials.
dc.language.isoenen
dc.publisherUniversity of Chesteren
dc.subjectbee productsen
dc.titleAn evaluation of the antioxidant and antimicrobial properties of bee products commercially available in the UKen
dc.typeThesis or dissertationen
dc.type.qualificationnameMScen
dc.type.qualificationlevelMasters Degreeen
html.description.abstractBee products such as honey and propolis have been used medicinally for centuries. More recent research has seen specific types of honey such as manuka honey used in wound healing and propolis as a constituent of mouthwashes and throat lozenges. The present study determined the antioxidant and antimicrobial activities of a number of widely available bee products in the UK. The disc diffusion method was utilised to assess the antibacterial activity of the bee products using a range of bacteria known to cause infection in humans. The ferric- reducing antioxidant power (FRAP) assay was utilised to assess the antioxidant activity of the bee products. The results demonstrated that bee products had antibacterial and antioxidant capacity but with considerable variation. The most potent effect was observed using manuka 30+ against S.epidermidis (33mm mean zone of inhibition when applied undiluted compared to 11mm when using standard honey). Other bee products were of much less potency including propolis which demonstrated no significant antimicrobial activity. However, the antioxidant capacity of propolis tablets was 95 µmol/l per 1mg/ml (95,000 µmol/l per 1 gram tablet). The most potent honey tested was manuka 30+ which was 9.0 µmol/l per 1mg/ml (4500µmol/l for a 5g portion) compared with standard honey 5.0 µmol/l per 1mg/ml (2500 µmol/l for a 5g portion).The antioxidant activity of propolis was also demonstrated in human saliva. The FRAP value of the saliva from a single human subject was evaluated following the intake of propolis containing lozenges compared with a control (boiled sweet). These biological effects may be significant in vivo and have particular relevant in the prevention in disease in humans. However, further work is needed in the form of randomised controlled trials.


Files in this item

Thumbnail
Name:
introductory materials.pdf
Size:
135.6Kb
Format:
PDF
Request:
Introductory Materials
Thumbnail
Name:
chapter 1.pdf
Size:
204.1Kb
Format:
PDF
Request:
Introduction
Thumbnail
Name:
chapter 2.pdf
Size:
117.3Kb
Format:
PDF
Request:
Methods
Thumbnail
Name:
chapter 3.pdf
Size:
250.6Kb
Format:
PDF
Request:
Results
Thumbnail
Name:
chapter 4.pdf
Size:
144.3Kb
Format:
PDF
Request:
Case Study
Thumbnail
Name:
chapter 5.pdf
Size:
174.9Kb
Format:
PDF
Request:
Discussion
Thumbnail
Name:
chapter 6.pdf
Size:
93.75Kb
Format:
PDF
Request:
Conclusion
Thumbnail
Name:
chapter 7.pdf
Size:
93.70Kb
Format:
PDF
Request:
Further Studies
Thumbnail
Name:
references.pdf
Size:
171.3Kb
Format:
PDF
Request:
References
Thumbnail
Name:
appendices.pdf
Size:
156.0Kb
Format:
PDF
Request:
Appendices

This item appears in the following Collection(s)

Show simple item record